Lv6
2450 积分 2023-09-03 加入
Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2– metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial
4个月前
已完结
A renaissance in targeting the PI3K/AKT/mTOR pathway
4个月前
已完结
Combinational therapies for the treatment of advanced cervical cancer
6个月前
已完结
Unmet needs in cervical cancer – can biological therapies plug the gap?
6个月前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
8个月前
已完结
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
8个月前
已完结
Single-Agent Divarasib in Patients With KRAS G12C –Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study
1年前
已完结
皖公网安备34019202002308
